Sarepta shares plunge 30% as future of its gene therapy appears at risk

Core Viewpoint - Shares of Sarepta Therapeutics experienced a significant decline of over 30% due to concerns regarding the future of its approved gene therapy treatment, Elevidys, following FDA intervention [1][2]. Group 1: FDA Actions - The FDA is requesting Sarepta Therapeutics to voluntarily halt all shipments of Elevidys, indicating potential regulatory challenges for the product [1]. - FDA Commissioner Marty Makary mentioned that the agency is evaluating whether Elevidys should remain on the market [2]. Group 2: Patient Safety Concerns - The FDA is investigating two patient deaths associated with Elevidys, raising serious safety concerns about the gene therapy [2]. - Additionally, Sarepta reported a third death linked to a different experimental gene therapy, further complicating the company's situation [2].